Two US-based groups and one group in China have investigated CD30 CAR-T cell therapy in heavily-pretreated R/R HL with ORR rates of 67, 63, and 39%, respectively (Table 3) [75–77]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.